In the pivotal phase of the admIRE trial, the VARIPULSE™ Platform demonstrated 85% peak primary effectiveness with minimal adverse events, short PFA application times, and low fluoroscopy exposure

在admIRE试验的关键阶段，VARIPULSE™平台显示出85%的峰值主要有效性，不良事件最少，PFA应用时间短，透视曝光率低

Additional findings presented at HRS show the potential of the VARIPULSE™ Platform in treating patients with diverse arrythmias

HRS上发表的其他发现显示了VARIPULSE™平台在治疗多种心律失常患者方面的潜力

IRVINE, Calif., May 17, 2024 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announced late-breaking results from the pivotal phase of the admIRE pivotal clinical trial, plus additional results from the VIRTUE study, presented at the Heart Rhythm Society (HRS) Annual Meeting in Boston from May 16-19.

加利福尼亚州欧文（IRVINE），2024年5月17日/PRNewswire/--全球心律失常治疗领导者、强生医疗技术公司（Johnson＆Johnson MedTech）的一部分Biosense Webster，Inc.宣布了admIRE关键临床试验关键阶段的最新突破性结果，以及5月16日至19日在波士顿举行的心律协会（HRS）年会上提交的美德研究的其他结果。

Both studies explore the potential of the VARIPULSE™ pulsed field ablation (PFA) Platform to treat patients with cardiac arrythmias including atrial fibrillation (AFib)..

这两项研究都探讨了VARIPULSE™脉冲场消融（PFA）平台治疗包括心房颤动（AFib）在内的心律失常患者的潜力。。

Twelve-month data from the pivotal phase of the admIRE study assessed the safety and efficacy of the VARIPULSE™ Platform among 277 participants with paroxysmal AFib treated across 30 healthcare centers in the U.S. by 39 operators. Presentation highlights include:1

admIRE研究关键阶段的12个月数据评估了VARIPULSE™平台的安全性和有效性，其中277名参与者在美国30家医疗中心接受了39名操作员的阵发性AFib治疗。演讲亮点包括：1

75% overall primary effectiveness successi

75%的总体主要有效性成功

85% peak primary effectiveness for participants receiving 73-96 PFA applications for PVIii

接受73-96 PFA PVIii申请的参与者的主要有效性峰值为85%

2.9% overall primary adverse event rateiii

总体主要不良事件发生率为2.9%III

There were no reported incidents of device or procedure-related death, atrioesophageal fistula, coronary spasm, or hemolysis-related renal failure requiring hemodialysis

没有报告与器械或手术相关的死亡，食道心房瘘，冠状动脉痉挛或需要血液透析的溶血相关肾衰竭的事件

100% of patients achieved acute procedural success;iv 98% first-pass isolation recorded per veinv

100%的患者取得了急性手术成功；iv每个veinv记录的98%首过隔离

Median procedure time of 81 minutes in pulmonary vein isolation (PVI)-only procedures, 90 minutes in all procedures, and a fluoroscopy time of 7 minutes

仅肺静脉隔离（PVI）手术的中位手术时间为81分钟，所有手术的中位手术时间为90分钟，透视时间为7分钟

43% of patients were able to leave the healthcare facility on the same day as their procedure

43%的患者能够在手术当天离开医疗机构

25% of procedures were performed without fluoroscopy, with no impact to safety or efficacy due to the full integration of the VARIPULSE™ Platform with the CARTO™ 3 System

25%的手术是在没有透视的情况下进行的，由于VARIPULSE™平台与CARTO™3系统的完全集成，对安全性或有效性没有影响

The admIRE study evaluated the safety and efficacy of the VARIPULSE™ Platform to treat paroxysmal atrial fibrillation (PAF), and supported the recent Premarket Approval Application to the U.S. Food & Drug Administration for the VARIPULSE™ Platform.

admIRE研究评估了VARIPULSE™平台治疗阵发性心房颤动（PAF）的安全性和有效性，并支持最近向美国食品和药物管理局提交的VARIPULSE™平台上市前批准申请。

The VARIPULSE™ Platform is not for sale in the United States

VARIPULSE™平台不在美国销售

'The admIRE study demonstrated good safety and effectiveness results. The primary effectiveness success was 74.6%, and among the subset of participants receiving 73-96 PFA applications for PVI, 85% achieved success. Primary safety events occurred in 2.9%, demonstrating promising evidence of the capabilities of the VARIPLUSE Platform,' said Vivek Reddy, M.D., director of electrophysiology, Mount Sinai Fuster Heart Hospital, New York.

“admIRE研究显示出良好的安全性和有效性结果。主要有效性成功率为74.6%，在接受73-96 PFA PVI申请的参与者中，85%取得了成功。纽约西奈山福斯特心脏医院电生理主任维韦克·雷迪（VivekReddy）医学博士说，主要安全事件发生率为2.9%，证明了VARIPLUSE平台的能力。

'Differentiated by its unique CARTO™ 3 System integration, this was the first PFA IDE study to support a substantial number of fluoro-free procedures; 25% of procedures were performed with zero fluoroscopy.'.

“由于其独特的CARTO™3系统集成而有所不同，这是第一个支持大量无氟程序的PFA IDE研究；25%的手术是在零透视下进行的。

Findings from the admIRE study build on previous data from the inspIRE study published earlier this year, which evaluated the efficacy and safety of the VARIPULSE™ Platform in patients with PAF in Europe and Canada. These latest data are part of Biosense Webster's comprehensive global clinical trial strategy across PFA solutions including the recently announced three-month results from the SmartfIRE clinical trial published in April 2024, the SmartPulse study announced in December 2023, and the Omny-IRE clinical trial announced in September 2023..

admIRE研究的结果基于今年早些时候发布的inspIRE研究的先前数据，该研究评估了VARIPULSE™平台在欧洲和加拿大PAF患者中的疗效和安全性。这些最新数据是Biosense Webster针对PFA解决方案的全面全球临床试验策略的一部分，包括最近宣布的2024年4月发布的SmartfIRE临床试验的三个月结果，2023年12月发布的SmartPulse研究以及2023年9月发布的Omny IRE临床试验。。

Data from the VIRTUE study were also presented at the HRS Annual Meeting, evaluating the further use of the investigational VARIPULSE™ Platform in patients more reflective of usual clinical practice, including patients with paroxysmal and persistent atrial fibrillation as well atypical atrial flutter, either as first-time or redo procedures.

来自美德研究的数据也在HRS年会上发表，评估了研究性VARIPULSE™平台在更能反映常规临床实践的患者中的进一步使用，包括阵发性和持续性心房颤动以及非典型心房扑动患者，无论是首次还是重做程序。

The inclusion criteria for VIRTUE extended beyond what is typical for catheter ablation trials and reflected the range of patients more commonly seen in clinical practice. For example, of the 125 patients in the VIRTUE trial, only 23% would have met the criteria for the admIRE trial. Ablation beyond PVI was performed in 80% of study participants.

美德的纳入标准超出了导管消融试验的典型标准，反映了临床实践中更常见的患者范围。例如，在美德试验的125名患者中，只有23%符合admIRE试验的标准。80%的研究参与者进行了PVI以外的消融。

The VARIPULSE™ Platform was demonstrated to be able to treat a variety of paroxysmal and persistent atrial fibrillation patients, as well as those with atypical atrial flutter, with lesions beyond PVI.2.

VARIPULSE™平台被证明能够治疗各种阵发性和持续性心房颤动患者，以及非典型心房扑动患者，病变超过PVI。

'Findings from the admIRE study add to our comprehensive PFA evidence generation strategy and continue to point to the safety and efficacy of the VARIPULSE™ Platform, and other PFA tools,' said Jennifer Currin, Ph.D., Vice President, Scientific Affairs, Cardiovascular & Specialty Solutions, Johnson & Johnson MedTech.

“admIRE研究的结果增加了我们全面的PFA证据生成策略，并继续指出VARIPULSE™平台和其他PFA工具的安全性和有效性，”强生医疗科技公司心血管与专业解决方案科学事务副总裁詹妮弗·柯林博士说。

'The breadth of data presented by Biosense Webster at this year's meeting underscores our commitment advancement of knowledge and innovation in the treatment of cardiac arrhythmias.'  .

“Biosense Webster在今年的会议上提供的大量数据突显了我们在心律不齐治疗方面的知识和创新的承诺。”。

AFib is the most common type of cardiac arrhythmia and affects more than 8 million people in the United States and nearly 50 million people worldwide.3 Approximately 1 in 4 adults over the age of 40 are at risk for developing AFib.4 Despite these projections, about one-third of patients with AFib are not aware they have the condition, and AFib often goes unrecognized until the onset of complications.5,6 Catheter ablation is a safe and effective procedure when drugs don't work to help restore the heart's incorrect electrical signals, which cause an abnormal heart rhythm.7.

AFib是最常见的心律失常类型，影响美国800多万人和全世界近5000万人[3]。40岁以上的成年人中约有四分之一有患AFib的风险[4]。尽管有这些预测，约三分之一的AFib患者不知道自己患有这种疾病，AFib通常在并发症发生之前无法被识别[5,6]。当药物无法帮助恢复导致心律异常的心脏错误电信号时，导管消融是一种安全有效的方法。

Additional information on Biosense Webster's data presented at HRS can be found here.

有关Biosense Webster在HRS上提供的数据的其他信息，请参见此处。

About the VARIPULSE™ PlatformThe VARIPULSE™ Platform is Biosense Webster's Irreversible Electroporation ablation system. The fully integrated platform includes the VARIPULSE™ Catheter, TRUPULSE™ Generator, and CARTO™ 3 Mapping System VARIPULSE™ Service Pack Software. In January 2024, Biosense Webster announced that the VARIPULSE™ Platform received its first regulatory approval from the Japan Ministry of Health, Labour and Welfare for the treatment of symptomatic drug refractory recurrent PAF using PFA.

关于VARIPULSE™平台VARIPULSE™平台是Biosense Webster的不可逆电穿孔消融系统。完全集成的平台包括VARIPULSE™导管、TRUPULSE™发生器和CARTO™3映射系统VARIPULSE™Service Pack软件。2024年1月，Biosense Webster宣布，VARIPULSE™平台首次获得日本厚生劳动省的监管批准，用于使用PFA治疗症状性药物难治性复发性PAF。

In Europe, the TRUPULSE™ generator received CE mark in late 2023 and the VARIPULSE™ Platform received CE mark in February 2024.  In the U.S., the VARIPULSE™ Catheter and TRUPULSE™ Generator are currently investigational and are not approved by regulatory authorities. In March 2024, Biosense Webster announced the submission of the VARIUPLSE™ Platform for Premarket Approval Application to the U.S.

在欧洲，TRUPULSE™发生器于2023年末获得CE标志，VARIPULSE™平台于2024年2月获得CE标志。在美国，VARIPULSE™导管和TRUPULSE™发生器目前正在研究中，尚未获得监管机构的批准。2024年3月，Biosense Webster宣布向美国提交VARIUPLSE™平台的上市前批准申请。

Food & Drug Administration..

美国食品药品监督管理局。。

About admIRE The admIRE study (Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the Biosense Webster IRE Ablation System) (NCT05293639) is a prospective, multi-center, single-arm study to demonstrate the safety and long-term effectiveness of the VARIPULSE™ Platform when used for isolation of pulmonary veins in treatment of patients in the United States with symptomatic drug refractory paroxysmal AFib.

关于admIRE admIRE研究（使用Biosense Webster IRE消融系统评估房颤治疗管理的安全性和有效性）（NCT05293639）是一项前瞻性，多中心，单臂研究，旨在证明VARIPULSE™平台在美国用于分离肺静脉治疗症状性药物难治性阵发性AFib患者时的安全性和长期有效性。

Pulmonary vein isolation (PVI) was achieved using the VARIPULSE™ Platform. The study consisted of a pilot phase, which assessed initial device safety and effectiveness, and a pivotal phase, which assessed these against pre-specified performance goals. The primary safety endpoint was incidence of early onset (within seven days) primary adverse events; atrioesophageal fistula (within 90 days); cardiac tamponade or perforation (within 30 days); and PV stenosis (within 12 months).

使用VARIPULSE™平台实现肺静脉隔离（PVI）。该研究包括一个试点阶段，评估初始设备的安全性和有效性，以及一个关键阶段，根据预先指定的性能目标评估这些。主要安全性终点是早期发作（7天内）主要不良事件的发生率；心房食管瘘（90天内）；心脏压塞或穿孔（30天内）；和PV狭窄（12个月内）。

Acute procedure success (defined as confirmed entrance block at the end of procedure) and freedom from documented atrial arrhythmia recurrence at 12 months were also assessed.  .

还评估了急性手术成功率（定义为手术结束时确诊的入口阻滞）和12个月时记录的房性心律失常复发情况。。

About VIRTUE The VIRTUE study is a collaborative, investigator-sponsored, prospective, single-center, nonrandomized, interventional clinical study to evaluate the safety and efficacy of using the Biosense Webster VARIPULSE™ Platform, inclusive of the VARIPULSE™ Catheter in combination with the TRPULSE™ Generator, and the compatible EAM system to treat patients with a variety of atrial arrhythmias during clinically-indicated ablation procedures.

关于美德美德研究是一项合作性，研究者赞助，前瞻性，单中心，非随机，介入性临床研究，旨在评估使用Biosense Webster VARIPULSE™平台的安全性和有效性，包括VARIPULSE™导管与TRPULSE™发生器的组合，以及兼容的EAM系统，用于在临床指示的消融过程中治疗各种房性心律失常患者。

A total of 125 evaluable subjects were enrolled including all types of AFib-related arrhythmias and were evaluated for 12 months post-procedure..

共纳入125名可评估受试者，包括所有类型的AFib相关心律失常，并在术后12个月进行评估。。

About Biosense Webster Biosense Webster, part of Johnson & Johnson MedTech, leads in cardiac arrhythmia diagnosis and treatment worldwide. We are dedicated to advancing electrophysiology and interventional cardiology tools and solutions for improved patient care.  Learn more at biosensewebster.com and connect on LinkedIn and X, formerly Twitter..

关于Biosense Webster Biosense Webster是强生医疗技术公司的一部分，在全球心律失常的诊断和治疗方面处于领先地位。我们致力于推进电生理学和介入心脏病学工具和解决方案，以改善患者护理。在biosensewebster.com上了解更多信息，并在LinkedIn和X（前身为Twitter）上进行连接。。

About Johnson & Johnson MedTechviiAt Johnson & Johnson MedTech,vii we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health.

关于Johnson＆Johnson MedTechviiAt Johnson＆Johnson MedTech，vii我们释放出多样化的医疗保健专业知识，有目的的技术和对人们的热情，以改变医疗干预的未来，并赋予每个人尽可能过上最好的生活。一个多世纪以来，我们推动了突破性的科学创新，以解决未满足的需求并重新想象健康。

In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized..

在外科、骨科、视觉和介入解决方案领域，我们将继续帮助挽救生命，创造一个医疗保健解决方案更加智能、微创和个性化的未来。。

Cautions Concerning Forward-Looking Statements  This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding the VARIPULSE™ Platform clinical trials. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Biosense Webster, Inc.

关于前瞻性声明的注意事项本新闻稿包含1995年《私人证券诉讼改革法案》中关于VARIPULSE™平台临床试验的“前瞻性声明”。这些声明基于当前对未来事件的预期。如果基础假设证明不准确或已知或未知的风险或不确定性出现，实际结果可能与Biosense Webster，Inc.的预期和预测有很大差异。

and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of healthcare products and services; and trends toward healthcare cost containment.

和/或强生公司。风险和不确定性包括但不限于：监管批准的不确定性；商业成功的不确定性；专利面临的挑战；竞争，包括技术进步、新产品和竞争对手获得的专利；导致产品召回或监管行动的产品功效或安全问题；适用法律法规的变更，包括全球医疗保健改革；医疗保健产品和服务购买者行为和消费模式的变化；以及医疗保健成本控制的趋势。

A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

有关这些风险、不确定性和其他因素的更多列表和描述，请参见强生公司截至2023年12月31日的10-K表年度报告，包括标题为“关于前瞻性声明的警示说明”和“项目1A”的章节。“风险因素”，以及强生公司随后在10-Q表上的季度报告以及向美国证券交易委员会提交的其他文件中。

Copies of these filings are available online at sec.gov, jnj.com or on request from Johnson & Johnson. Neither of Biosense Webster, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments..

这些文件的副本可在sec.gov、jnj.com或强生公司的要求下在线获得。Biosense Webster，Inc.和强生公司均不承诺因新信息或未来事件或发展而更新任何前瞻性声明。。

i. Primary effectiveness was defined as 12-month freedom from documented (symptomatic or asymptomatic) atrial tachyarrhythmia (atrial fibrillation [AF]/atrial tachycardia [AT]/atrial flutter [AF]) episodes of ≥30 seconds duration based on rhythm monitoring during the post-blanking evaluation period (day 91-365), as well as freedom from other failure modes: failure to achieve entrance block in all PVs; >1 repeat ablation for atrial tachyarrhythmia during the 3-month blanking period or any repeat ablation during the evaluation period; use of a nonstudy catheter to treat the PVs and/or to ablate left atrial non-PV AF targets during the index procedure or to perform a repeat procedure during the 3-month blanking period; taking new or previously failed Class I/III AADs at greater doses during the evaluation period; continuous AF/AT/AFL of unknown origin during the evaluation period; or direct-current cardioversion during the evaluation period for AF/AT/AFL recurrences.

i、 主要有效性定义为在消隐后评估期间（第91-365天）根据节律监测，12个月内无记录（有症状或无症状）房性快速性心律失常（房颤[房颤]/房性心动过速[房颤]/心房扑动[房颤]）发作持续时间≥30秒，以及无其他故障模式：未能在所有PV中实现入口阻滞；>1在3个月的消隐期内重复消融房性快速性心律失常或在评估期间重复消融；在索引过程中使用非研究导管治疗PVs和/或消融左心房非PV AF靶标，或在3个月的消隐期内进行重复手术；在评估期间以更大剂量服用新的或以前失败的I/III类AAD；在评估期间，持续的AF/AT/AFL来源不明；或在AF/AT/AFL复发的评估期间进行直流电复律。

The protocol defined performance goal is 50%.ii. Peak primary effectiveness was defined in a post-hoc analysis as receiving 73-96 applications for PVI (n=85).iii.  Primary adverse events were defined as: Device- or procedure- related death, major vascular access complications or bleeding, myocardial infarction, pericarditis, heart block, permanent phrenic nerve paralysis, stroke, thromboembolism, transient ischemic attack, pulmonary edema, and vagal nerve injury/gastroparesis within 7 days of the index ablation.

协议定义的性能目标为50%。在事后分析中，主要有效性峰值定义为接受73-96例PVI申请（n=85）。主要不良事件定义为：器械或手术相关死亡，主要血管通路并发症或出血，心肌梗塞，心包炎，心脏传导阻滞，永久性膈神经麻痹，中风，血栓栓塞，短暂性脑缺血发作，肺水肿和迷走神经损伤/胃轻瘫在指数消融后7天内。

PAEs also included cardiac tamponade/perforation occurring up to 30 days postprocedure, atrioesophageal fistula occurring up to 90 days post-procedure, and PV stenosis occurring anytime during the 12-month follow-up period. The protocol-defined performance goal is 12%.iv. Acute procedural success was d.

PAEs还包括术后30天内发生的心脏压塞/穿孔，术后90天内发生的心房食管瘘，以及12个月随访期间随时发生的PV狭窄。协议定义的性能目标为12%。iv.急性程序成功是d。

© Johnson & Johnson Biosense Webster, Inc. 2024. All rights reserved. M_US_BWI_THER_370349

©强生生物传感器韦伯斯特公司，2024年。保留所有权利。M\u US\u BWI\u THER\u 370349

1 Reddy VY, Calkins H, Mansour M, et al. Long-term Safety and Effectiveness After Paroxysmal Atrial Fibrillation Pulsed Field Ablation From the U.S. Multicenter admIRE Study. Late-breaker LB-469804-04 presented at: Heart Rhythm Society 2024; May 17; Boston, MA.2 Musikantow D, Reddy V. Pulsed Field Ablation to Treat Atrial Fibrillation and Related Arrhythmias Resembling Usual Clinical Practice: Initial Results of VIRTUE [abstract].

1 Reddy VY，Calkins H，Mansour M等人。美国多中心admIRE研究中阵发性心房颤动脉冲场消融后的长期安全性和有效性。晚破者LB-469804-04发表于：心律协会2024；5月17日；波士顿，马萨诸塞州。2 Musikantow D，Reddy V。脉冲场消融治疗心房颤动和相关心律失常，类似于常规临床实践：美德的初步结果[摘要]。

In: Heart Rhythm Society Annual Meeting.; May 16-19; Boston.3 Mensah, G, Fuster, V, Murray, C. et al. Global Burden of Cardiovascular Diseases and Risks, 1990-2022. J Am Coll Cardiol. 2023 Dec, 82 (25) 2350–2473. https://doi.org/10.1016/j.jacc.2023.11.0074 Staerk, et al. 2018 Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study.

在：心律协会年会上。；5月16-19日；波士顿。3 Mensah，G，Fuster，V，Murray，C。等人，《1990-2022年全球心血管疾病和风险负担》。J Am Coll Cardiol。2023年12月，82（25）2350–2473。https://doi.org/10.1016/j.jacc.2023.11.0074Staerk等人2018年根据最佳，临界或升高水平的危险因素，心房颤动的终生风险：基于弗雷明汉心脏研究纵向数据的队列研究。

doi: 10.1136_bmj.k1453 | BMJ 2018;361:k14535 Dilaveris PE, Kennedy HL. Silent atrial fibrillation: epidemiology, diagnosis, and clinical impact. Clin Cardiol. 2017;40:413–418. 6 Benjamin EJ, Go AS, Desvigne-Nickens P et al. Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.

doi:10.1136ーbmj.k1453 | bmj 2018；361:k14535 Dilaveris PE，Kennedy HL。无症状心房颤动：流行病学，诊断和临床影响。临床心脏病学。2017年；40:413-418。6 Benjamin EJ，Go AS，Desvigne Nickens P等人。心房颤动筛查的研究重点：国家心肺血液研究所虚拟研讨会的报告。

Circulation. 2021;143:372–388.7 Natale, A. Reddy VY, Monir G, et al. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. Journal of the American College of Cardiology, 2014;64(7),647–656. doi: 10.1016/j.jacc.2014.04.072.

流通。2021年；143:372–388.7 Natale，A。Reddy VY，Monir G等人。使用接触力感应导管进行阵发性房颤导管消融：前瞻性多中心SMART-AF试验的结果。美国心脏病学会杂志，2014；64（7），647-656。doi:10.1016/j.jacc.2014.04.072。

Media contact:

媒体联系人：

Investor Relations:

投资者关系：

Diane Pressman

黛安·普雷斯曼

Tracy Menkowski

Tracy Menkowski

Dpressm1@its.jnj.com

Dpressm1@its.jnj.com

investor-relations@its.jnj.com

investor-relations@its.jnj.com

Charlene DeBar

夏琳·德巴尔

Cdebar1@its.jnj.com

Cdebar1@its.jnj.com

SOURCE Biosense Webster

来源Biosense Webster